TGA's decision to not register lecanemab (LEQEMBI)
Published
Related content
-
Lapse of provisional registration for Tecentriq (atezolizumab) for the treatment of locally advanced or metastatic triple negative breast cancer (mTNBC)
Provisional registration of Tecentriq (atezolizumab) for the treatment in mTNBC will lapse on 22 March 2023. -
Update on Psilocybin and MDMA scheduling
The Scheduling Delegate has decided to seek further advice in relation to psilocybin and MDMA -
TGA provisionally approves AstraZeneca's COVID-19 vaccine
The TGA has granted provisional approval to AstraZeneca Pty Ltd for its COVID-19 vaccine